Working… Menu

Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02825160
Recruitment Status : Recruiting
First Posted : July 7, 2016
Last Update Posted : June 7, 2021
Information provided by (Responsible Party):

Brief Summary:
This study is collecting post-marketing information on the safety and effectiveness of Ventavis under the routine clinical practice for patients with PAH

Condition or disease Intervention/treatment
Hypertension, Pulmonary Drug: Ventavis (Iloprost, BAYQ6256)

Detailed Description:

This local, prospective, non-interventional, company sponsored, multi-center, single-cohort study includes patients treated with Ventavis for PAH. A total of 270 patients (valid for safety analysis) is planned to be enrolled in 5 years. Target population is patients with PAH diagnosis. This study is performed as an all-patient investigation, therefore all patients who receive Ventavis treatment for PAH need to be registered. The treatment should be performed based on the product label in Japan. The standard observation period will last for 12 months from starting Ventavis treatment. In addition, the extension observation will be carried out as long as Ventavis treatment continues or at most for more 4 years. The standard observation points are 3 month and

1 to 5 years.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 270 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Drug Use Investigation of Ventavis for Pulmonary Arterial Hypertension (PAH)
Actual Study Start Date : August 1, 2016
Estimated Primary Completion Date : March 31, 2022
Estimated Study Completion Date : September 27, 2023

Group/Cohort Intervention/treatment
Ventavis treatment group
Drug: Ventavis (Iloprost, BAYQ6256)
The treatment of Ventavis should comply with the local product information

Primary Outcome Measures :
  1. Number of participants with treatment emergent adverse events (TEAE) of special interest. [ Time Frame: Up to 5 years ]

    TEAE of special interest:

    • Hypotension
    • Syncope
    • Local irritation
    • Bleeding events
    • Thrombocytopenia
    • Tachycardia

  2. Number of participants with adverse drug reaction [ Time Frame: Up to 5 years ]

Secondary Outcome Measures :
  1. Change from baseline in Pulmonary Vascular Resistance (PVR) after 3 and 12 months [ Time Frame: Baseline and 3 months,Baseline and 12 months, ]
  2. Change from baseline in 6-Minute Walking Distance after 3 and 12 months [ Time Frame: Baseline and 3 months,Baseline and 12 months ]
  3. Change from baseline in tricuspid regurgitation pressure gradient (TRPG) after 3 and 12 months [ Time Frame: Baseline and 3 months,Baseline and 12 months ]
  4. Change in blood concentration from baseline in brain natriuretic peptide / N-terminal pro-brain natriuretic peptide (BPN/NT-pro BNP) after 3 and 12 months. [ Time Frame: Baseline and 3 months,Baseline and 12 months ]
  5. Change from baseline in WHO functional class after 3 and 12 months [ Time Frame: Baseline and 3 months,Baseline and 12 months, ]
  6. Time to Clinical Worsening [ Time Frame: Up to 5 years ]

    The 1st occurrence date of one of the following events is recorded and used for the calculation of time to clinical worsening:

    • Death (all-cause mortality), -Heart/lung transplantation, -Atrial Septostomy,
    • Hospitalization due to persistent worsening of Pulmonary Hypertension (PH),
    • Start of new PH specific treatment or modification of a preexisting Prostacycline analogues treatment except Ventavis due to worsening PH,
    • Persistent decrease in 6MWD due to worsening PH,
    • Persistent worsening of WHO functional class due to deterioration of PH

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Study population includes PAH patients treated with Ventavis. This study is performed as an all-case investigation. Therefore, all patients who have been treated with Ventavis for PAH need to be registered in principle, until the target number of patients reached.

Inclusion Criteria:

  • Patients diagnosed with PAH
  • Patients for whom the decision to initiate treatment with Ventavis was made as per investigator's routine treatment practice.

Exclusion Criteria:

- N/A

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02825160

Layout table for location contacts
Contact: Bayer Clinical Trials Contact (+) 1-888-8422937

Layout table for location information
Many Locations Recruiting
Multiple Locations, Japan
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Layout table for additonal information
Responsible Party: Bayer Identifier: NCT02825160    
Other Study ID Numbers: 17941
First Posted: July 7, 2016    Key Record Dates
Last Update Posted: June 7, 2021
Last Verified: June 2021
Keywords provided by Bayer:
Prostacycline analogue
Pulmonary arterial hypertension
Post-marketing surveillance
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Platelet Aggregation Inhibitors
Vasodilator Agents